Peer-reviewed veterinary case report
Serum HMGB1 levels predict chemotherapy outcome in dogs with lymphoma
By Meyer, A et al.·Published in Veterinary and comparative oncology·2010·University of Bremen, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: High-mobility group B1 proteins in canine lymphoma: prognostic value of initial and sequential serum levels in treatment outcome following combination chemotherapy.
- Species:
- dog
Plain-English summary
A group of 16 dogs with lymphoma had their blood tested for a protein called HMGB1 before starting chemotherapy and during treatment. The results showed that dogs with higher initial levels of HMGB1 were less likely to achieve complete remission compared to those with lower levels. Additionally, changes in HMGB1 levels during treatment could help predict how long the remission would last. This suggests that monitoring HMGB1 levels could be useful for veterinarians in managing lymphoma in dogs and determining treatment outcomes.
People also search for: dog lymphoma treatment · HMGB1 levels in dogs · chemotherapy for dogs with cancer
Abstract
Elevated high-mobility group box 1 (HMGB1) levels have been demonstrated in different human neoplasias. Information on serum HMGB1 before and during chemotherapy is lacking, as is data pertaining to its prognostic significance. The aim of this study was to characterize serum HMGB1 level in dogs with lymphoma and to assess its influence on the outcome following chemotherapy. Serum HMGB1 concentrations were measured in 16 dogs with lymphoma before treatment (W1) and on weeks 2 (W2), 6 (W6) and 12 (W12) of treatment with chemotherapy. Initial serum HMGB1 levels were significantly higher than HMGB1concentrations in control dogs and the levels in W2, W6 and W12. HMGB1-W1 concentrations were lower in dogs achieving complete remission than that in the single dog with partial remission. The ratio W12/W6 exhibited significant influence on remission duration. In these dogs with lymphoma, serum HMGB1 was elevated in comparison with that in controls. Initial serum HMGB1 level and its modulation during treatment may possess prognostic value.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20579326/